Prophylactic NAC to Improve Platelet Engraftment After Haploidentical Transplantation in Severe Aplastic Anemia Patients
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: N-acetylcysteine.
- Who it may be relevant to
- Registry conditions: Aplastic Anemia. Basic parameters: 14 years — 50 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- Center list to be confirmed — check the primary protocol.
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
Prophylactic N-Acetylcysteine to Facilitate Platelet Engraftment Following Haploidentical Hematopoietic Stem Cell Transplantation for Patients With Severe Aplastic Anemia: A Prospective Multicenter Randomized Controlled Trial
Overview
This study aims to evaluate the efficacy and safety of prophylactic oral N-acetylcysteine (NAC) for facilitating platelet engraftment in patients with severe aplastic anemia (SAA) receiving haploidentical hematopoietic stem cell transplantation (haplo-HSCT). This is a prospective, multicenter, randomized controlled trial enrolling a total of 142 patients with SAA scheduled for their first haplo-HSCT, who will be randomly assigned at a 1:1 ratio to the NAC prophylaxis group or the control group, with 71 subjects in each arm. Patients in the intervention group will receive oral NAC 400 mg three times daily from Day -14 before transplantation to Day +60 post-transplant, while the control group will receive no prophylactic NAC, with all other transplant-related treatments identical between the two groups. The primary endpoint is the cumulative platelet engraftment rate at 2 months after transplantation. Secondary endpoints cover neutrophil engraftment rate, incidence of poor hematopoietic reconstitution, cumulative blood product transfusion volume, graft-versus-host disease (GVHD), overall survival, GVHD-free and failure-free survival, and biomarkers reflecting bone marrow hematopoietic microenvironment reconstruction. Safety outcomes will be assessed via adverse events graded per NCI CTCAE Version 5.0. Statistical analyses will be performed using R 4.4.0 software, primarily adopting competing risk models and the Kaplan-Meier method based on full analysis set, per-protocol set and safety set. This trial will clarify intergroup differences in platelet recovery, other efficacy endpoints and safety profiles, verify the clinical benefits and safety of NAC, and generate high-quality clinical evidence for prophylactic intervention targeting platelet engraftment after haplo-HSCT in SAA patients to optimize clinical management strategies.
Interventions
- Drug N-acetylcysteine
Oral N-acetylcysteine capsules, 400 mg per dose, administered three times daily. Treatment starts at Day -14 before transplantation and continues until Day +60 after transplantation.
Primary outcome measures
- Cumulative incidence of platelet engraftment at 2 months after transplantation [Time frame: 2 months post-HSCT]
Secondary outcome measures (7)
- Cumulative incidence of neutrophil engraftment at 2 months after transplantation [Time frame: 2 months post-HSCT]
- Incidence of poor hematopoietic reconstitution at 2 months post-transplant [Time frame: 2 months post-HSCT]
- Cumulative volume of blood product transfusions [Time frame: From pre-transplant Day -14 to post-transplant Day +60]
- Cumulative incidence of acute and chronic graft-versus-host disease (GVHD) [Time frame: 100 days for aGVHD; 1 year for cGVHD after transplantation]
- 1-year overall survival (OS) [Time frame: 1 year after transplantation]
- 1-year graft-versus-host disease-free/failure-free survival (GFFS) [Time frame: 1 year after transplantation]
- Bone marrow endothelial progenitor cell (EPC) count and intracellular ROS level [Time frame: Baseline (pre-transplant), post-transplant 1 months and 2 months]
Eligibility criteria
Inclusion criteria
- Diagnosed with aplastic anemia and scheduled to receive first haplo-HSCT
- Aged 14 to 50 years
- Hematopoietic Cell Transplant Comorbidity Index (HCT-CI) ≤ 2
- Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2
- Negative donor-specific HLA antibodies
- No uncontrolled active infection before transplantation
- No irreversible severe organ dysfunction
- Voluntarily sign written informed consent and agree to complete scheduled follow-up
Exclusion criteria
- Confirmed allergy or hypersensitivity to NAC
- Medical history of bronchial asthma
- Uncontrolled severe psychiatric disorders unable to cooperate with treatment and follow-up
- Active peptic ulcer, gastrointestinal bleeding, inflammatory bowel disease or severe gastrointestinal dysfunction
- Female patients who are pregnant or breastfeeding
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Allocation
- Randomized
- Model
- Parallel assignment
- Masking
- Open label
- Primary purpose
- Prevention
Study locations
Center list to be confirmed — check the primary protocol.
Identifiers
NCT: NCT07737262 · 2026PHD022-001